TY - JOUR
T1 - Practices of Referring Patients to Advanced Heart Failure Centers
AU - IDEAL-HF investigators
AU - Herr, Jared J.
AU - Ravichandran, Ashwin
AU - Sheikh, Farooq H.
AU - Lala, Anuradha
AU - Chien, Christopher V.
AU - Hsiao, Stephanie
AU - Srivastava, Ajay
AU - Pedrotty, Dawn
AU - Nowaczyk, Jennifer
AU - Tompkins, Shannon
AU - Ahmed, Sara
AU - Xiang, Fei
AU - Forest, Stephen
AU - Tong, Michael Z.
AU - D'souza, Benjamin
N1 - Funding Information:
JJH has received research grants and has served as a speaker and consultant for Abbott Laboratories; MZT has received speaker honoraria and consulting fees for Abiomed and Abbott Laboratories; FS has received consulting fees and research support from Pfizer, consulting fees and research support from Alnylam, consulting fees from Eidos, consulting fees from Akcea, speaker honoraria and research support from Abbott Laboratories; AR has received speaker honoraria from Abbott Laboratories and Medtronic; CC has received consultant fees from Abbott Laboratories and Boston Scientific; AS has received honoraria from Abbott Laboratories and Abiomed; BD'S has received speaker honorarium from Abbott Laboratories and St. Jude Medical; all other authors declare no disclosures.
Publisher Copyright:
© 2021 Elsevier Inc.
PY - 2021/11
Y1 - 2021/11
N2 - Background: Therapies for advanced heart failure (AHF) improve the likelihood of survival in a growing population of patients with stage D heart failure (HF). Successful implementation of these therapies is dependent upon timely and appropriate referrals to AHF centers. Methods: We performed a retrospective analysis of patients referred to 9 AHF centers for evaluation for AHF therapies. Patients’ demographics, referring providers’ characteristics, referral circumstances, and evaluation outcomes were collected. Results: The majority of referrals (n = 515) were male (73.4%), and a majority of those were in the advanced state of the disease: very low left ventricular ejection fraction (<20% in 51.5%); 59.4% inpatient; and high risk Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) profiles (74.5% profile 1–3). HF cardiologists (49.1%) were the most common originating referral source; the least common (4.9%) were electrophysiologists. Common clinical triggers for referral included worsening HF (30.0%), inotrope dependence (19.6%), hospitalization (19.4%), and cardiogenic shock (17.8%). Most commonly, AHF therapies were not offered because patients were too sick (38.0%–45.1%) or for psychosocial reasons (20.3%–28.6%). Compared to non-HF cardiologists, patients referred by HF cardiologists were offered an AHF therapy more often (66.8% vs 58.4%, P = 0.0489). Of those not offered any AHF therapy, 28.4% received home inotropic therapy, and 14.5% were referred to hospice. Conclusions: In this multicenter review of AHF referrals, HF cardiologists referred the most patients despite being a relatively small proportion of the overall clinician population. Late referral was prevalent in this high-risk patient population and correlates with worsened outcomes, suggesting a significant need for broad clinician education regarding the benefits, triggers and appropriate timing of referral to AHF centers for optimal patient outcomes.
AB - Background: Therapies for advanced heart failure (AHF) improve the likelihood of survival in a growing population of patients with stage D heart failure (HF). Successful implementation of these therapies is dependent upon timely and appropriate referrals to AHF centers. Methods: We performed a retrospective analysis of patients referred to 9 AHF centers for evaluation for AHF therapies. Patients’ demographics, referring providers’ characteristics, referral circumstances, and evaluation outcomes were collected. Results: The majority of referrals (n = 515) were male (73.4%), and a majority of those were in the advanced state of the disease: very low left ventricular ejection fraction (<20% in 51.5%); 59.4% inpatient; and high risk Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) profiles (74.5% profile 1–3). HF cardiologists (49.1%) were the most common originating referral source; the least common (4.9%) were electrophysiologists. Common clinical triggers for referral included worsening HF (30.0%), inotrope dependence (19.6%), hospitalization (19.4%), and cardiogenic shock (17.8%). Most commonly, AHF therapies were not offered because patients were too sick (38.0%–45.1%) or for psychosocial reasons (20.3%–28.6%). Compared to non-HF cardiologists, patients referred by HF cardiologists were offered an AHF therapy more often (66.8% vs 58.4%, P = 0.0489). Of those not offered any AHF therapy, 28.4% received home inotropic therapy, and 14.5% were referred to hospice. Conclusions: In this multicenter review of AHF referrals, HF cardiologists referred the most patients despite being a relatively small proportion of the overall clinician population. Late referral was prevalent in this high-risk patient population and correlates with worsened outcomes, suggesting a significant need for broad clinician education regarding the benefits, triggers and appropriate timing of referral to AHF centers for optimal patient outcomes.
KW - Cardiomyopathy
KW - Heart failure
KW - Transplantation
UR - http://www.scopus.com/inward/record.url?scp=85111029232&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85111029232&partnerID=8YFLogxK
U2 - 10.1016/j.cardfail.2021.05.024
DO - 10.1016/j.cardfail.2021.05.024
M3 - Article
C2 - 34146684
AN - SCOPUS:85111029232
SN - 1071-9164
VL - 27
SP - 1251
EP - 1259
JO - Journal of Cardiac Failure
JF - Journal of Cardiac Failure
IS - 11
ER -